搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
ENDPOINTS NEWS
4 小时
BARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to ...
ENDPOINTS NEWS
4 小时
EMA reviews hair loss products following concerns about suicidal thoughts
The European Medicines Agency is looking more closely at medicines used to treat hair loss and a condition caused by an ...
ENDPOINTS NEWS
6 小时
Alnylam agrees to drop patent lawsuit against Moderna over Covid-19 vaccine
Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...
ENDPOINTS NEWS
6 小时
RSV vaccines off to a sluggish start in US this season, with volumes behind 2023
This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking ...
ENDPOINTS NEWS
6 小时
J&J discontinues mid-stage dengue study, citing deprioritization of com ...
What’s left of Johnson & Johnson’s infectious disease work continues to shrink, after the company announced Friday that it ...
ENDPOINTS NEWS
12 小时
After $14B exit, Karuna co-founder finds next bet; Ex-Regenxbio CEO Ken Mills heads ...
Andrew Miller has quickly made his first move after the technology he invented, KarXT, secured an FDA approval last week. The ...
ENDPOINTS NEWS
11 小时
Sanofi sells rare disease drug Enjaymo to Recordati for $825M upfront
Sanofi is offloading its rare autoimmune disease medicine Enjaymo to an Italian pharmaceutical company for $825 million ...
ENDPOINTS NEWS
9 小时
Biotech's third quarter was relatively bright — with a few caveats
The weather is getting cooler, but biotech’s recovery is heating up. After a years-long wait-and-see game exhausted many ...
ENDPOINTS NEWS
9 小时
Editas sells CRISPR fees to Vertex for $57M upfront; Plus, news about Oncolyt ...
DRI Healthcare Trust is paying $57 million upfront to the gene editing company in exchange for future licensing payments from Vertex, which struck an agreement with Editas to use its CRISPR/Cas9 gene ...
ENDPOINTS NEWS
1 天
Flagship partners with key Singapore R&D agency as it boosts APAC investment
Flagship Pioneering's roots in Singapore are growing less than a year after the biotech incubator first unveiled its ...
ENDPOINTS NEWS
1 天
Eli Lilly resolves shortage for tirzepatide, potentially ending compounder ...
Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...
ENDPOINTS NEWS
1 天
End of obesity drug shortage threatens patient access to compounded shots ...
Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈